AbbVie Inc (ABBV)vsAurinia Pharmaceuticals Inc (AUPH)
ABBV
AbbVie Inc
$253.35
+4.20%
HEALTHCARE · Cap: $447.62B
AUPH
Aurinia Pharmaceuticals Inc
$17.55
-3.24%
HEALTHCARE · Cap: $2.26B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 20959% more annual revenue ($62.82B vs $298.30M). AUPH leads profitability with a 100.0% profit margin vs 5.8%. AUPH trades at a lower P/E of 8.1x. AUPH earns a higher WallStSmart Score of 69/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
AUPH
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.3%
Fair Value
$146.22
Current Price
$253.35
$107.13 premium
Intrinsic value data unavailable for AUPH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 100 of every $100 in revenue as profit
Strong operational efficiency at 53.3%
Earnings expanding 56.3% YoY
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 100.0% and operating margin at 53.3%. Revenue growth of 24.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : AUPH
No major red flags identified for AUPH, but monitor valuation.
Key Dynamics to Monitor
ABBV profiles as a value stock while AUPH is a growth play — different risk/reward profiles.
AUPH carries more volatility with a beta of 1.43 — expect wider price swings.
AUPH is growing revenue faster at 24.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
AUPH scores higher overall (69/100 vs 63/100), backed by strong 100.0% margins and 24.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?